Phosphorus Is Part Of A Ring Patents (Class 514/110)
-
Publication number: 20120237508Abstract: The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.Type: ApplicationFiled: March 20, 2012Publication date: September 20, 2012Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
-
Publication number: 20120237502Abstract: The present invention relates to a method for the prevention or treatment of certain breast cancers or ovarian cancer comprising administering to a patient in need thereof of a therapeutically effective amount of a 17,20-lyase inhibitor, wherein the breast cancer or ovarian cancer is estrogen receptor (ER) negative.Type: ApplicationFiled: November 18, 2011Publication date: September 20, 2012Applicant: Takeda Pharmaceutical Company LimitedInventor: James W. Darnowski
-
Publication number: 20120230972Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.Type: ApplicationFiled: May 22, 2012Publication date: September 13, 2012Inventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H.R. Feling
-
Publication number: 20120225061Abstract: The present invention provides a compound of formula (I): as further described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.Type: ApplicationFiled: March 1, 2012Publication date: September 6, 2012Inventors: Matthew Burger, Yu Ding, Wooseok Han, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Aaron R. Smith, Victoriano Tamez, JR., Huw Tanner, Lifeng Wan
-
Publication number: 20120219615Abstract: The present invention is directed generally to formulations of a TLR agonist preferably a TLR8 agonist, and its use in the treatment of various diseases, including combination therapies for treating cancer.Type: ApplicationFiled: October 3, 2011Publication date: August 30, 2012Applicants: The Trustees of the University of Pennsylvania, VentiRx Pharmaceuticals, Inc.Inventors: Robert Hershberg, George Coukos, Gregory Dietsch, Andrea Facciabene, Kristi Manjarrez, Tressa D. Randall
-
Publication number: 20120219522Abstract: The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: ApplicationFiled: February 21, 2012Publication date: August 30, 2012Inventor: Ning XI
-
Publication number: 20120207856Abstract: Methods for treating a patient at risk for or diagnosed with colorectal cancer are disclosed herein. The method of the present invention determines the overall expression of MSH3 in cells suspected of being colorectal cancer cells from the patient and predicting the efficacy of therapy with a genotoxic anti-neoplastic agent for treating the patient, wherein a decrease in the overall expression of MSH3 in the patient cells when compared to the expression of MSH3 in normal colorectal cells indicates a predisposition to responsiveness to genotoxic anti-neoplastic agent therapy, wherein the therapy comprises administering an effective amount of the genotoxic anti-neoplastic agent therapy to patients.Type: ApplicationFiled: February 10, 2012Publication date: August 16, 2012Applicant: Baylor Research InstituteInventors: Ajay Goel, C. Richard Boland, Minoru Koi, Masanobu Takahashi
-
Publication number: 20120201747Abstract: This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.Type: ApplicationFiled: February 2, 2012Publication date: August 9, 2012Applicant: POP TEST CORTISOL LLCInventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
-
Patent number: 8236820Abstract: Compounds of the general formula are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.Type: GrantFiled: August 11, 2008Date of Patent: August 7, 2012Inventor: Basil Rigas
-
Publication number: 20120189623Abstract: The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds:Type: ApplicationFiled: April 3, 2012Publication date: July 26, 2012Inventors: Rustum Boyce, Eric Martin, Weibo Wang, Hong Yang, Paul A. Barsanti
-
Publication number: 20120183535Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.Type: ApplicationFiled: December 29, 2011Publication date: July 19, 2012Applicant: Pharmacyclics, Inc.Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
-
Publication number: 20120183593Abstract: This invention provides a polymeric drug delivery system including a hydrogel containing one or more drugs for the treatment of a posterior segment disease. Allowing passive transference of this drug from a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concentrations of compounds, e.g., from eye drops.Type: ApplicationFiled: November 18, 2010Publication date: July 19, 2012Inventor: Clyde Schultz
-
Publication number: 20120148577Abstract: A lymphocytotoxic, but hematopoietic stem cell-sparing, high-dose amount of an oxazaphosphorine drug such as, for example, cyclophosphamide, administered post-transplantation can be used to reduce transplant rejection, including graft-versus-host-disease (GVHD). In some embodiments, the transplants are bone marrow transplants or hematopoietic stem cell transplants carried out for the treatment of hematologic disorders, including hematologic malignancies and non-malignant hematologic disorders. In some embodiments, the transplants are carried out for the treatment of hereditary hemoglobinopathies, such as sickle cell anemia and thalassemia.Type: ApplicationFiled: October 13, 2011Publication date: June 14, 2012Applicants: ACCENTIA BIOPHARMACEUTICALS, INC., JOHNS HOPKINS UNIVERSITYInventors: EPHRAIM J. FUCHS, LEO LUZNIK, ROBERT A. BRODSKY, RICHARD J. JONES, FRANCIS E. O'DONNELL, JR., CARLOS SANTOS, SUSAN BONITZ
-
Publication number: 20120148595Abstract: The present invention relates to GABA-linked anthracycline-lipid conjugates and to methods of using the conjugates to treat cancer. Methods for making the GABA-linked anthracycline lipid conjugates are also provided.Type: ApplicationFiled: March 11, 2010Publication date: June 14, 2012Applicant: Luitpold Pharmaceuticals, Inc.Inventors: Charles S. Swindell, Glenn G. Fegley, Hema M. Sundar, Richard Lawrence
-
Publication number: 20120135089Abstract: The present invention provides, e.g., compounds having the structure of formula (I): The present invention also provides pharmaceutical compositions that include such compounds, and methods for modulating murine double minute 2 protein (Mdm2) E3 ligase activity, particularly the Mdm2-MdmX hetero-complex E3 ligase activity, using such compounds.Type: ApplicationFiled: March 17, 2010Publication date: May 31, 2012Inventors: Brent R. Stockwell, Ariel Herman
-
Publication number: 20120134987Abstract: New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.Type: ApplicationFiled: December 15, 2011Publication date: May 31, 2012Inventors: Matthew T. Burger, Wooseok Han, Jiong Lan, Gisele Nishiguchi
-
Publication number: 20120134986Abstract: Measurement of a single gene expressed by tumor cells (LMO2) and a single gene expressed by the immune microenvironment (TNFRSF9), which determination may be referred to herein as a two gene score (TGS), powerfully predicts overall survival in patients with NHL, particularly overall survival in the context of anthracycline-based chemotherapy or co-treatment with anthracycline-based chemotherapy and anti-CD20 immunotherapy. It is shown herein that increased levels of LMO2 and TNFRSF9 correlate with a positive patient response and improved prognosis.Type: ApplicationFiled: October 5, 2011Publication date: May 31, 2012Inventors: Arash Ash Alizadeh, Ronald Levy, Andrew J. Gentles, Izidore S. Lossos
-
Publication number: 20120134959Abstract: The invention relates to pyrimidine compounds of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.Type: ApplicationFiled: April 15, 2010Publication date: May 31, 2012Applicant: Wyeth LLCInventors: Kevin Joseph Curran, Joshua Aaron Kaplan, David James Richard, Jeroen Cunera Verheijen, Arie Zask
-
Publication number: 20120134955Abstract: The invention is to provide a novel anticancer agent or sensitizer for cancer chemotherapy or radiotherapy. A compound of a general formula (I): wherein A means an aryl group or a heteroaryl group, or a group of a formula (a):; R1 means a —(C?O)aOb(C1-C6)alkyl group, a —(C?O)aOb(C2-C6)alkenyl group, a —(C?O)aOb(C3-C6)cycloalkyl group, an aryl group or a heteroaryl group; R2 and R3 each mean a hydrogen atom, a halogen atom, a hydroxyl group, a carboxyl group, a —(C?O)aOb(C1-C6)alkyl group or a group of —(C?O)aN(R1e)R2e; R4 means a hydrogen atom or a (C1-C6)alkyl group, and the like have an excellent Wee 1-kinase-inhibitory effect, and are therefore useful in the field of medicine, especially in the field of various cancer treatments.Type: ApplicationFiled: February 18, 2010Publication date: May 31, 2012Inventors: Yasuhiro Goto, Kenji Niyama, Satoshi Sunami, Keiji Takahashi
-
Publication number: 20120128662Abstract: The present invention relates to substituted imidazoquinoxaline compounds of general formula (I) as inhibitors of Mps-1 Kinase or TTK, and being active against inflammation and cancer.Type: ApplicationFiled: April 24, 2010Publication date: May 24, 2012Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Marcus Koppitz, Benjamin Bader, Ulf Bömer, Bertolt Kreft, Philip Lienau, Tobias Marquardt, Stefan Prechtl, Gerhard Siemeister, Christof Wegscheid-Gerlach
-
Publication number: 20120121502Abstract: The present invention relates to novel pyrimidine hydroxy amide compounds, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.Type: ApplicationFiled: November 15, 2011Publication date: May 17, 2012Applicant: ACETYLON PHARMACEUTICALSInventors: John H. van Duzer, Ralph Mazitschek, Yanbing Ding, Nan Yu, Yun Cao, Yong Liu
-
Publication number: 20120121536Abstract: Glucose deprivation is an attractive strategy in cancer research and treatment. Cancer cells upregulate glucose uptake and metabolism for maintaining accelerated growth and proliferation rates. Specifically blocking these processes is likely to provide new insights to the role of glucose transport and metabolism in tumorigenesis, as well as in apoptosis. As solid tumors outgrow the surrounding vasculature, they encounter microenvironments with a limited supply of nutrients leading to a glucose deprived environment in some regions of the tumor. Cancer cells living in the glucose deprived environment undergo changes to prevent glucose deprivation-induced apoptosis. Knowing how cancer cells evade apoptosis induction is also likely to yield valuable information and knowledge of how to overcome the resistance to apoptosis induction in cancer cells.Type: ApplicationFiled: March 24, 2011Publication date: May 17, 2012Applicant: OHIO UNIVERSITYInventors: Xiaozhuo Chen, Stephen Bergmeier
-
Publication number: 20120114765Abstract: Disclosed are novel compounds which are useful as therapeutics, especially in anti-neoplastic therapy and in other therapeutic regimes where cysteine protease inhibition is implicated.Type: ApplicationFiled: March 31, 2010Publication date: May 10, 2012Inventors: Ping Cao, Joseph Weinstock, William D. Kingsbury, Craig A. Leach, Suresh Kumar Kizhakkethil-George, Benjamin Nicholson
-
Publication number: 20120107323Abstract: The invention provides compounds capable of treating a subject suffering from or being susceptible to a cell proliferative disorder (especially, cancer), methods of identifying and using the compounds, pharmaceutical compositions and kits thereof.Type: ApplicationFiled: March 12, 2010Publication date: May 3, 2012Applicant: University of FloridaInventors: Steven N. Hochwald, David A. Ostrov, William G. Cance, Elena Kurenova
-
Publication number: 20120107230Abstract: The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders.Type: ApplicationFiled: October 25, 2011Publication date: May 3, 2012Applicants: UNIVERSITY OF OREGONInventors: JOHN G. CURD, JOHN F.W. KEANA, ALSHAD S. LALANI, PAUL B. WESTBERG, BRADFORD GOODWIN, W. DAVID HENNER
-
Publication number: 20120093729Abstract: Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.Type: ApplicationFiled: December 19, 2011Publication date: April 19, 2012Applicant: METABASIS THERAPEUTICS, INC.Inventors: Mark D. ERION, K. Raja REDDY, Serge H. BOYER
-
Publication number: 20120087915Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.Type: ApplicationFiled: June 3, 2011Publication date: April 12, 2012Applicant: Pharmacyclics, Inc.Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
-
Publication number: 20120082703Abstract: The present invention relates to pharmaceutical compositions comprising polyfunctional metal phenolates that have biological applications as an anticancer adjuvant, cytoprotective antimetastatic agents and antimutagenic agents when associated with chemotherapy drugs. The present invention further relates to the use of said polyfunctional metal phenolates in the preparation of drugs for the treatment, prophylaxis or prevention of neoplasic diseases in humans and animals.Type: ApplicationFiled: November 11, 2009Publication date: April 5, 2012Applicant: UNIVERSIDADE BANDEIRANTE DE SAO PAULO-ACADEMIA PAULISTA ANCHETA S/C LTDAInventors: José AgustÃn Quincoces Suárez, Durvanei Augusto Maria, Paulo Celso Pardi, Fernanda Faião Flores, Reginaldo Pereira Santos, Daniela Gonçales Rando
-
Publication number: 20120070410Abstract: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.Type: ApplicationFiled: November 5, 2009Publication date: March 22, 2012Inventors: Julius L. Apuy, Darren E. Insko, Joyce J. James
-
Publication number: 20120064036Abstract: The embodiments provide methods of administering a high dose or a loading dose of a TPO modulator to a subject. The embodiments further provide methods of treating thrombocytopenia and/or neutropenia in a subject. Additionally, the embodiments further provide methods of increasing platelet production and/or enhancing the number of peripheral blood stem cells in a subject.Type: ApplicationFiled: May 27, 2010Publication date: March 15, 2012Inventors: Connie L. Erickson-Miller, Julian Jenkins
-
Publication number: 20120045412Abstract: The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.Type: ApplicationFiled: October 28, 2011Publication date: February 23, 2012Applicant: Gilead Sciences, Inc.Inventors: Lawrence S. Melvin, JR., Michael Graupe, Chandrasekar Venkataramani, Juan A. Guerrero
-
Publication number: 20120040020Abstract: The present disclosure relates to pyrazine compounds of formula I: wherein L, n, R1, and R2 are as described in the specification. These compounds are useful as inhibitors of ATR protein kinase. The disclosure also relates to pharmaceutically acceptable compositions comprising the compounds of the disclosure; methods of treating of various diseases, disorders, and conditions using the compounds of the disclosure; processes for preparing the compounds of the disclosure; intermediates for the preparation of the compounds of the disclosure; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.Type: ApplicationFiled: October 27, 2011Publication date: February 16, 2012Applicant: Vertex Pharmaceuticals IncorporatedInventors: Jean-Damien Charrier, Steven John Durrant, David Kay, Michael O'Donnell, Ronald Marcellus Alphonsus Knegtel, Somhairle MacCormick, Joanne Pinder, Stephen Clinton Young, Haley Marie Binch, Thomas Cleveland, Lev Tyler Dewey Fanning, Dennis James Hurley, Pramod Joshi, Urvi Jagdishbhai Sheth, Alina Silina, Philip Michael Reaper, Anisa Nizarali Virani
-
Publication number: 20120034216Abstract: The present invention relates to spiroketal compounds that are useful in methods of treating or preventing protozoal infections, parasitic infections, bacterial infections, cell proliferative disorders and anti inflammatory disorders. The spiroketal compounds are also useful as immunosuppressive agents, and also in methods of controlling pests.Type: ApplicationFiled: August 11, 2011Publication date: February 9, 2012Applicant: ECOBIOTICS LTDInventors: Paul Warren Reddell, Victoria Anne Gordon
-
Publication number: 20120020877Abstract: An intrauterine device and more specifically an intracervical device (ICD) for the local release of drugs in the loco-regional treatment of tumours of the uterine cervix comprises an elongated stem (2) to be positioned in the cervical canal (15), this stem consisting of an inner hollow core (3) and a coating (4) containing a gradual-release drug, the stem being attached to: a first element (5) for blocking the stem (2) inside the uterine cavity (12), and located at the cranial or upper end; a second blocking element (7, 71) positioned inside the vagina (11), against the ectocervix (16), located at the caudal or lower end of the stem (2).Type: ApplicationFiled: January 29, 2009Publication date: January 26, 2012Applicant: Fondazione IRCSSInventor: Francesco Raspagliesi
-
Publication number: 20120021036Abstract: The invention provides nanostructures or products of manufacture for use as ex vivo or in vivo composition (e.g., a drug, or a therapeutic, diagnostic or imaging reagent) delivery vehicles. In one aspect, the invention provides nanoparticles comprising several compartments which in unison function as a composite nanostructure. In one embodiment, the nanoparticles of the invention comprise a combination of polymer core/lipid bilayer interface which incorporate covalently attached lipid-vascular targeting ligands. These composite nanoparticles can deliver highly effective and selective payloads for diagnostic, prophylactic or therapeutic applications.Type: ApplicationFiled: January 14, 2010Publication date: January 26, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Bharat Majeti, Eric Murphy, Wolfgang Wrasidlo, David Cheresh
-
Publication number: 20120014915Abstract: The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases) and more particularly. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these ThI-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the postpartum period.Type: ApplicationFiled: September 26, 2006Publication date: January 19, 2012Inventor: Rhonda Voskuhl
-
Publication number: 20120009141Abstract: A compound of Formula 1: or a salt thereof, and methods for the use thereof, especially as an IAP inhibitor, as well as related compounds, compositions, and methods.Type: ApplicationFiled: August 7, 2009Publication date: January 12, 2012Applicant: PHARMASCIENCE INC.Inventors: Alain Laurent, Melanie Proulx, James B. Jaquith, Irina Denissova
-
Patent number: 8093230Abstract: The invention concerns the use of mercaptoethane sulfonate-sodium (Mesna) to increase the solubility of Ifosfamide in storage-stable, concentrated and/or highly-concentrated (supersaturated) aqueous pharmaceutical preparations, storage-stable, concentrated and/or highly-concentrated (supersaturated) aqueous pharmaceutical Ifosfamide preparations for parenteral administration as well as a process for their production.Type: GrantFiled: September 28, 2004Date of Patent: January 10, 2012Assignee: Baxter International Inc.Inventor: Berthold Roessler
-
Publication number: 20120003228Abstract: The invention relates to means and methods for determining whether a subject is at high or low risk of autoimmune disease progression by determining the CD8 or CD4 cell subtype of the subject. Autoimmune diseases of particular interest include vasculitis, systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. The invention also relates to means and methods for determining the CD8 or CD4 cell subtype of a subject, e.g. for predicting responses to infection, vaccination and/or transplantation.Type: ApplicationFiled: January 20, 2010Publication date: January 5, 2012Applicant: Cambridge Enterprise LimitedInventors: Ken Smith, Paul Lyons, Eoin McKinney
-
Publication number: 20110319365Abstract: The present disclosure concerns complexes of 4-hydroperoxy ifosfamide. In one embodiment the complexes can be represented by the formula wherein A represents an ammonium species selected from the conjugate acid of a basic amino acid, quaternary ammonium, aliphatic ammonium, heterocyclic ammonium, aromatic ammonium, substituted and unsubstituted pyridinium, guanidinium, and amidinium, and wherein X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyperproliferative disorders, also are disclosed.Type: ApplicationFiled: February 24, 2010Publication date: December 29, 2011Inventor: Lee Roy Morgan
-
Publication number: 20110312904Abstract: The present invention provides compounds of Formula (I), compositions comprising an effective amount of a compound of Formula (I), optionally with chemotherapeutic drugs such as a tubulin-binding drug, and methods of their use for reducing the toxicity of cytotoxic agents, treating or preventing cancer or a neuropathic disorder, inducing a chemoprotective phase II enzyme, DNA, or protein synthesis, enhancing the immune system, treating inflammation, improving and enhancing general health or well-being, and methods for making compounds of Formula (I).Type: ApplicationFiled: August 27, 2009Publication date: December 22, 2011Applicants: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Samuel J. Danishefsky, Ting-Chao Chou, Xiaoguang Lei, Heedong Yun, Fay Ng, John Hartung, Dalibor Sames
-
Publication number: 20110311648Abstract: Compositions and methods for the treatment of malignancy and chronic viral infection are disclosed.Type: ApplicationFiled: July 20, 2011Publication date: December 22, 2011Inventors: George C. Prendergast, Alexander J. Muller, James B. DuHadaway, William Malachowski
-
Patent number: 8080536Abstract: Novel cyclic phosphoramidate prodrugs of drugs of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.Type: GrantFiled: September 24, 2010Date of Patent: December 20, 2011Assignee: Metabasis Therapeutics, Inc.Inventors: Mark D. Erion, K. Raja Reddy, Serge H. Boyer
-
Publication number: 20110295189Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.Type: ApplicationFiled: August 8, 2011Publication date: December 1, 2011Applicants: Tokyo Univ. of Sci. Edu. Fdn. Admin. Org., Kowa Co., Ltd.Inventors: Toshio INAGI, Makoto Kanebako, Hiroshi Terada, Kimiko Makino, Masakazu Toi
-
Publication number: 20110293610Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.Type: ApplicationFiled: August 12, 2011Publication date: December 1, 2011Applicant: HUMAN GENOME SCIENCES, INC.Inventors: Steven M. RUBEN, Steven C. BARASH, Gil H. CHOI, Tristan VAUGHAN, David HILBERT
-
Publication number: 20110293744Abstract: Inhibitors of poly(ADP-ribose)polymerase having a structure of Formula (I), ways to make them and methods of treating patients using them are disclosed.Type: ApplicationFiled: January 19, 2010Publication date: December 1, 2011Applicant: ABBOTT LABORATORIESInventors: Magdalena K. Przytulinska, Thomas D. Penning, Yunsong Tong
-
Publication number: 20110269706Abstract: The disclosure includes hydroxamic compounds of Formula I: (I) wherein P, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.Type: ApplicationFiled: January 7, 2010Publication date: November 3, 2011Applicant: Northlake Biosciences LLCInventors: Yu Chen, Yi Chen
-
Publication number: 20110262398Abstract: Disclosed herein are reagents and methods for detecting and treating age-related diastolic dysfunction in an animal or a human.Type: ApplicationFiled: April 21, 2011Publication date: October 27, 2011Applicant: UNIVERSITY OF ILLINOISInventors: Samuel C. Dudley, Roy L. Sutliff
-
Publication number: 20110256128Abstract: The present invention provides triazole compounds of Formula I: as further described herein. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, and a method of treating a disorder mediated, at least in part, by KSP in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of Formula I.Type: ApplicationFiled: April 13, 2011Publication date: October 20, 2011Inventors: Tinya ABRAMS, Paul A. BARSANTI, Yu DING, David DUHL, Wooseok HAN, Cheng HU, Yue PAN
-
Publication number: 20110256212Abstract: 8-quinolinol (8Q) and derivatives thereof for use in the treatment of proliferative diseases such as cancer, in particular slow metabolizing quiescent cancer stem cells.Type: ApplicationFiled: February 22, 2011Publication date: October 20, 2011Applicant: The Johns Hopkins UniversityInventors: Ying Zhang, Jiangbing Zhou, Hao Zhang